Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Idenix receives EU approval for hepatitis drug
Idenix plans to launch the once-a-day oral treatment for adult patients with chronic hepatitis B in the second quarter of 2007 beginning with the UK and Germany. In
Idenix plans to launch the once-a-day oral treatment for adult patients with chronic hepatitis B in the second quarter of 2007 beginning with the UK and Germany. In
Inspire anticipates launching AzaSite in the latter part of the third quarter of 2007 and expects to generate $30 – $45 million in sales in the 2008 calendar
Veramyst is the first prescription nasal steroid spray to demonstrate consistent and significant improvement in relieving overall allergic eye symptoms, which included red, itchy and watery eyes, in
In addition, stockholders voted to defeat stockholder proposals regarding: disclosing the company’s animal welfare policy; preparing a report on limiting the supply of prescription drugs in Canada, and
Merck is seeking market authorization for Arcoxia to treat osteoarthritis in the US, where it has been under review since December 2003. The drug is in the same
Based upon the positive recommendation, marketing authorization by the European Commission is expected in two to three months. Soliris, a designated orphan medicinal product, is intended to reduce
The acquired portfolio include CNS drug Seresta, an anti-anxiety agent used for sleep disorders and substance-withdrawal symptoms. No employees will transfer from Wyeth to Meda in conjunction with
The FDA indicated that Cipher’s application is approvable subject to the resolution of two remaining issues. In addition to one question related to chemistry, manufacturing and controls, the
The company said it anticipates receiving the marketing authorisation from the European Commission by mid-year 2007. The paliperidone prolonged release tablets marketing authorisation application is based on an
Humira will be the first self-administered biologic for the treatment of Crohn’s disease. This is an important milestone for Abbott, as Crohn’s disease will be the fourth approved